Influenza

H1N1 is the most prevalent flu virus circulating this year, resulting in a less severe flu season overall than last year when H3N2 was predominant.

A new report links early treatment of influenza A/H3N2 with the drug to a 30% decrease in mortality.

Researchers have found that the microbiome in the respiratory tract contributes to how susceptible we each are to the flu. Work is underway to use this data to create a preventive tool

A new study reveals that llama antibodies may be effective in offering protection against numerous flu strains in a single vaccine

A new report highlights how flu vaccination rates decline as the day progresses, and how primary care practices can use ‘nudges’ to modify patient care behaviors.

A new vaccine in development could provide increased flu protection for seniors.

It’s too early yet to say whether last year’s devastating flu season will motivate more patients to receive flu shots, but so far it looks like a good year for the vaccine.

NasoVax is still in the development stages but may eventually provide an option for patients who are immunocompromised.

A new one-dose antiviral-the first treatment approved to fight the flu in 20 years-will be available to clinicians this flu season.

The intranasal vaccine is back, and changes have been made to the viral composition of this year’s vaccine.